MA

Mainz BioMed N.V.

Develops at-home diagnostic tests for the early detection of life-threatening cancers.

F

Overview

Corporate Details

ISIN(s):
NL0015000LC2 (+3 more)
LEI:
894500XWJE7LIJNYQ547
Country:
Germany
Address:
Robert-Koch-Strasse 50, 55129 Mainz
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mainz BioMed N.V. is a molecular genetics company that develops and commercializes market-ready in-vitro diagnostic (IVD) solutions for the early detection of life-threatening conditions. The company's flagship product, ColoAlert®, is a non-invasive, at-home screening test for colorectal cancer (CRC) marketed in Europe. Mainz BioMed is also advancing its product pipeline with proprietary genetic testing methods for other deadly conditions, including pancreatic cancer, to provide accessible and reliable early detection solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 15:00
Regulatory News Service
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel …
English 12.2 KB
2025-09-30 14:01
Regulatory News Service
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Sc…
English 12.1 KB
2025-09-23 14:01
Regulatory News Service
Mainz Biomed Announces Commercial Launch of ColoAlert in Switzerland
English 11.5 KB
2025-09-02 14:01
Regulatory News Service
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
English 11.2 KB
2025-08-13 14:01
Regulatory News Service
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert
English 11.6 KB
2025-07-23 14:01
Business and Financial Review
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for…
English 11.2 KB
2025-07-15 14:01
Earnings Release
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colore…
English 15.5 KB
2025-06-25 14:01
Regulatory News Service
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Scr…
English 11.1 KB

Automate Your Workflow. Get a real-time feed of all Mainz BioMed N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Mainz BioMed N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Hana Pharm. Co., Ltd. Logo
Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.
South Korea 293480
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea 128940
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A
HELLENIC DYNAMICS PLC Logo
Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.
United Kingdom HELD
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea 376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS

Talk to a Data Expert

Have a question? We'll get back to you promptly.